Wealth Enhancement Advisory Services, LLC Fate Therapeutics Inc Transaction History
Wealth Enhancement Advisory Services, LLC
- $61.1 Billion
- Q3 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 38,743 shares of FATE stock, worth $40,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,743
Previous 35,347
9.61%
Holding current value
$40,292
Previous $39,000
23.08%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
154Shares Held
83.7MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$13.4 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.8MShares$9.15 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.73 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.51 Million1.27% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $101M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...